RecruitingPhase 2NCT06451861

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Randomized Study of ABC-14 Regimen ( AZA, Venetoclax and Chidamide) Compared With "3+7" Standard Induction Therapy or AB-14 (Venetoclax Combined With Azacitidine) for Newly Diagnosed Acute Myeloid Leukemia

Sponsor

Guangdong Provincial People's Hospital

Enrollment

240 participants

Start Date

Aug 21, 2024

Study Type

INTERVENTIONAL

Conditions

Acute Myeloid Leukemia

Summary

To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study compares a new chemotherapy combination (ABC-14 regimen) against the standard "3+7" induction chemotherapy for newly diagnosed acute myeloid leukemia (AML) — a blood cancer that requires urgent treatment. Researchers want to see if the new combination is more effective. **You may be eligible if...** - You are 18 or older and have been newly diagnosed with AML (not the APL subtype) - You have not yet received any systemic treatment for leukemia (except medications to temporarily reduce white blood cell counts) - You are able to take medications by mouth **You may NOT be eligible if...** - You have a known allergy to the study drugs - You have previously been resistant to azacitidine or venetoclax - You have uncontrolled serious infections or major organ failure (heart, liver, or kidneys) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGChidamide

Induction Therapy

DRUGVenetoclax

Induction Therapy

DRUGazacitidine

Induction Therapy

DRUGAnthracyclines or anthraquinones

Induction Therapy

DRUGcytarabine

Induction Therapy

Locations(13)

Dongguan General Hosptial

Dongguan, Guangdong, China

Foshan First People's Hospital

Foshan, Guangdong, China

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

The Fifth Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

The First Affiliated Hospital of Guangdong Pharmaceutical University

Guangzhou, Guangdong, China

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

The First Affiliated Hospital of Jinan University

Guangzhou, Guangdong, China

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Shenzhen second people's Hospital

Shenzhen, Guangdong, China

Affiliated Hospital of Guangdong Medical University

Zhanjiang, Guangdong, China

Zhuhai General Hosptial

Zhuhai, Guangdong, China

Hainan General Hosptial

Haikou, Hainan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06451861

Related Trials

Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia

NCT072434835 locations

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

NCT072959511 location

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649221 locations

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

NCT06672146124 locations

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390346 locations